OrthoPediatrics (NASDAQ:KIDS) Stock Price Up 6.2%

Shares of OrthoPediatrics Corp. (NASDAQ:KIDS - Get Free Report) rose 6.2% on Tuesday . The stock traded as high as $29.87 and last traded at $29.61. Approximately 64,894 shares changed hands during trading, a decline of 63% from the average daily volume of 175,902 shares. The stock had previously closed at $27.88.

Wall Street Analyst Weigh In

KIDS has been the subject of several recent analyst reports. JMP Securities restated a "market outperform" rating and set a $50.00 price objective on shares of OrthoPediatrics in a research report on Thursday, March 7th. Truist Financial downgraded OrthoPediatrics from a "buy" rating to a "hold" rating and dropped their price objective for the stock from $39.00 to $31.00 in a research report on Thursday, January 25th.

OrthoPediatrics Stock Up 9.0 %

The company has a debt-to-equity ratio of 0.03, a current ratio of 5.44 and a quick ratio of 2.90. The stock has a market capitalization of $715.92 million, a P/E ratio of -33.04 and a beta of 1.16. The firm has a 50-day simple moving average of $27.62 and a 200 day simple moving average of $28.71.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last posted its earnings results on Wednesday, March 6th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.05. The firm had revenue of $37.61 million during the quarter, compared to the consensus estimate of $37.59 million. OrthoPediatrics had a negative return on equity of 5.03% and a negative net margin of 14.10%. On average, equities research analysts forecast that OrthoPediatrics Corp. will post -1.34 EPS for the current year.

Insider Activity

In other news, General Counsel Daniel J. Gerritzen sold 2,741 shares of the stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $27.59, for a total value of $75,624.19. Following the completion of the sale, the general counsel now owns 52,403 shares of the company's stock, valued at $1,445,798.77. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, Director Mark C. Throdahl sold 2,433 shares of the firm's stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $27.59, for a total transaction of $67,126.47. Following the completion of the sale, the director now owns 137,857 shares of the company's stock, valued at $3,803,474.63. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, General Counsel Daniel J. Gerritzen sold 2,741 shares of the firm's stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $27.59, for a total value of $75,624.19. Following the sale, the general counsel now directly owns 52,403 shares of the company's stock, valued at approximately $1,445,798.77. The disclosure for this sale can be found here. Over the last quarter, insiders sold 17,253 shares of company stock valued at $477,375. Company insiders own 32.60% of the company's stock.

Institutional Investors Weigh In On OrthoPediatrics

Large investors have recently added to or reduced their stakes in the business. Point72 Hong Kong Ltd acquired a new stake in OrthoPediatrics during the first quarter worth approximately $26,000. CWM LLC boosted its holdings in OrthoPediatrics by 16,283.3% in the fourth quarter. CWM LLC now owns 983 shares of the company's stock worth $32,000 after acquiring an additional 977 shares in the last quarter. Almanack Investment Partners LLC. bought a new position in OrthoPediatrics in the third quarter worth approximately $34,000. RiverPark Advisors LLC bought a new position in OrthoPediatrics in the third quarter worth approximately $35,000. Finally, International Assets Investment Management LLC boosted its holdings in OrthoPediatrics by 3,151.4% in the fourth quarter. International Assets Investment Management LLC now owns 1,203 shares of the company's stock worth $37,000 after acquiring an additional 1,166 shares in the last quarter. Institutional investors and hedge funds own 69.05% of the company's stock.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.